ReNewVax are pleased to announce the appointment of Dr Miguel Leon-Rios as Head of Research.
An experienced immunologist, Miguel has been intimately involved in the translational development of our lead program RVX-001, both during his time at the University of Liverpool and since joining ReNewVax early-2023. Miguel’s expertise includes using preclinical in vivo models and ex vivo human cell-based and organoid assays to elucidate the immunogenicity and protective efficacy of novel vaccines and therapeutics.
Commenting on Miguel’s appointment, Neil Murray, ReNewVax’s CEO said, “I’m delighted to see Miguel assume the role of Head of Research for ReNewVax. He has played a pivotal role in the development of our pipeline – particularly our lead program, RVX-001, which is the first universal vaccine for S. pneumoniae. His expertise and scientific leadership will be key to the company as we drive RVX-001 towards first in human clinical studies.”
Separately, Marie O’Brien, who was Chief Scientific Officer, has left ReNewVax having decided to pursue new opportunities and is moving on to the next chapter of her professional journey.
Dr. Murray said, “On behalf of the Board, we wish to thank Marie for her contributions to the business and wish her all the best in her future endeavours.”